Sign Up
Stories
Aldeyra Therapeutics R&D Day 2024
Share
4D Molecular Therapeutics Raises $300 Mi...
ABIONYX Pharma Files 2023 Document
ACTICOR BIOTECH: Financial Report Postpo...
AI-Powered Antigen Research Partnership
BioNTech's mRNA Cancer Vaccine Progress
Breakthrough Animal Study for EVX-B1 Vac...
Overview
API
Aldeyra Therapeutics will conduct a Research & Development Day in April 2024, showcasing pipeline programs for immune-mediated and metabolic diseases. The event will spotlight RASP modulators ADX‑629, ADX‑246, and ADX‑248, aiming to enhance pathways and lower toxicity.
Ask a question
How could the outcomes of the R&D Day influence Aldeyra Therapeutics' market position and partnerships?
How might the development of RASP modulators impact the treatment landscape for immune-mediated diseases?
What potential challenges could Aldeyra Therapeutics face in optimizing protein systems with their pharmaceuticals?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage
Mar